Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis
Background Ibrutinib and acalabrutinib are Bruton tyrosine kinase inhibitors used in the treatment of B‐cell lymphoproliferative disorders. Ibrutinib is associated with new‐onset atrial fibrillation. Cases of sinus bradycardia and sinus arrest have also been reported following ibrutinib treatment. C...
Guardado en:
Autores principales: | Jari M. Tuomi, Loryn J. Bohne, Tristan W. Dorey, Hailey J. Jansen, Yingjie Liu, Douglas L. Jones, Robert A. Rose |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5b8c21de6e6247fe86ccf4e7765fb41d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence
por: Andrei A. Petrenko, et al.
Publicado: (2021) -
Ibrutinib-associated atrial fibrillation treatment with catheter ablation
por: Ridhima Kapoor, MD, et al.
Publicado: (2021) -
Study of Sinoatrial Nodal Artery Dominance in Brazilian Human Hearts
por: Bezerra,Frank Silva, et al.
Publicado: (2008) -
ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia
por: Tatiana E. Bialik, et al.
Publicado: (2021) -
Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib
por: Juan Carlo Avalon, et al.
Publicado: (2021)